Abstract
Major advances in the understanding of genetic iron overload have led to a clarification of the nosology and terminology of the related diseases. The term hemochromatosis should be reserved to the entities where iron overload is related to hepcidin deficiency or hepcidin resistance. The diagnosis of hemochromatosis is non-invasive, based on clinical examination, blood investigations and, whenever possible, magnetic resonance imaging. Phlebotomies remain the mainstay of the treatment, but new therapeutic approaches should, in the future, constitute a valuable advance, hopefully both as an adjunct to bleeding in the induction phase and as its replacement in the maintenance phase. The goal of the present review is to update the terminology of hemochromatosis in light of major pathophysiological advances, and the main features of its diagnostic and therapeutic approaches.
Article PDF
Avoid common mistakes on your manuscript.
References
Ganz T. The discovery of the iron-regulatory hormone hepcidin. Clin Chem 2019;65;1330–1.
Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 2020;105;260–72.
Brissot P, Ropert M, Le Lan C, Loréal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012;1820;403–10.
Le Lan C, Loréal O, Cohen T, Ropert M, Glickstein H, Lainé F, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005;105;4527–31.
Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers 2018;4;18016.
Pilling LC, Tamosauskaite J, Jones G, Wood AR, Jones L, Kuo CL, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ 2019;364;k5222.
Drakesmith H, Nemeth E, Ganz T. Ironing out ferroportin. Cell Metab 2015;22;777–87.
Kaphan E, Laurin D, Lafeuillade B, Drillat P, Park S. Impact of transfusion on survival in patients with myelodysplastic syndromes: current knowledge, new insights and transfusion clinical practice. Blood Rev 2020;41;100649.
Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol 2018;107;55–63.
Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: a framework for changing the management of iron deficiency. Lancet Haematol 2020;7;e342–e50.
Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and anemia: a tight relationship. Front Physiol 2019;10;1294.
Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med 2019;133;69–74.
Pietrangelo A. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 2017;102;1972–84.
Piperno A, Alessio M. Aceruloplasminemia: waiting for an efficient therapy. Front Neurosci 2018;12;903.
Kenawi M, Rouger E, Island ML, Leroyer P, Robin F, Rémy S, et al. Ceruloplasmin deficiency does not induce macrophagic iron overload: lessons from a new rat model of hereditary aceruloplasminemia. FASEB J 2019;33;13492–502.
Porto G, Brissot P, Swinkels DW, Zoller H, Kamarainen O, Patton S, et al. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet 2016;24;479–95.
Henninger B, Alustiza J, Garbowski M, Gandon Y. Practical guide to quantification of hepatic iron with MRI. Eur Radiol 2020;30;383–93.
Vlasveld LT, Janssen R, Bardou-Jacquet E, Venselaar H, Hamdi-Roze H, Drakesmith H, et al. Twenty years of ferroportin disease: a review or an update of published clinical, biochemical, molecular, and functional features. Pharmaceuticals (Basel) 2019;12;132.
Bardou-Jacquet E, Lainé F, Guggenbuhl P, Morcet J, Jézéquel C, Guyader D, et al. Worse outcomes of patients with HFE hemochromatosis with persistent increases in transferrin saturation during maintenance therapy. Clin Gastroenterol Hepatol 2017;15;1620–7.
Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52;1671–779.
Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 2012;120;3829–36.
Richard F, van Lier JJ, Roubert B, Haboubi T, Göhring UM, Dürrenberger F. Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am J Hematol 2020;95;68–77.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Brissot, P., Brissot, E. What’s Important and New in Hemochromatosis?. Clin Hematol Int 2, 143–148 (2020). https://doi.org/10.2991/chi.k.200726.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.k.200726.001